Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia: Vaccines against P. aeruginosa pneumonia
Saeko Hamaoka, Yoshifumi Naito, Hideya Katoh, [...], Teiji Sawa
Article Efficacy comparison of adjuvants in PcrV vaccine against Pse...
The reason might be that Pseudomonas aeruginosa is a facultative pathogen, which is known for its potential to cause nosocomial infections, infections of the ear, eyes and lungs, and which is a serious threat in CF patients. Therefore, and with the exception of CF patients, the target population for a vaccine is hard to define. If talking about nosocomial pneumonia, which patient group should receive a vaccine and when – taking into account that it takes several days to weeks at least until a protective immune response is raised. By the way – but this is a different topic – prevention of nosocomial pneumonia may also be achieved by hygiene and infection control measurements.
LPS- and flagellin-based vaccines for preventing infection in CF-patients have been (and might still be) under development, but have failed to show protection. When talking about CF there are several problems which may hamper successful vaccine development, all above the mucus, which itself protects bacteria from the direct action of antibodies.
A recent Cochrane review reported on six trials, from which only two were further analyzed. There was no benefit from a P. aeruginosa vaccine, the “risk of getting a chronic infection did not decrease and lung function was similar in both groups of cystic fibrosis patients”. The authors concluded that “vaccines (…) cannot be recommended.” (Reference: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001399.pub4/abstract;jsessionid=D50854FEF12ED47698734B902A17EF72.f03t02)
Hi DR.this article can help you.
Article Efficacy comparison of adjuvants in PcrV vaccine against Pse...
hi doctor
which is known for its potential to cause nosocomial infections, infections of the ear, eyes and lungs, and which is a serious threat in CF patients. Therefore, and with the exception of CF patients, the target population for a vaccine is hard to define. If talking about nosocomial pneumonia, which patient group should receive a vaccine and when – taking into account that it takes several days to weeks at least until a protective immune response is raised. By the way – but this is a different topic – prevention of nosocomial pneumonia may also be achieved by hygiene and infection control measurements.
مراحب يا ورد
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521563/
Hi Dr.Muthanna Hussain
Effective treatment and control of P. aeruginosa infections remains a persistent problem, primarily because of the natural resistance of the organism and its remarkable ability to acquire resistance to multiple antimicrobial agents by various mechanisms.1 As an alternative strategy to prevent P. aeruginosa infections in susceptible populations effective immunotherapies or vaccines against P. aeruginosa have long been sought after.
no efficient and marketable vaccine against P. aeruginosa infections is currently available.
But recent reports list P. aeruginosa among the most serious antibiotic-resistant bacteria and one for which effective vaccines are needed
The observation that genetic immunization, more commonly referred to as DNA vaccination, is able to elicit an immune response has fostered a new generation in vaccine development
Production of an effective immune response against selected target antigens has been successfully demonstrated using recombinant retroviral vectors
Other details in the following link with my best wishes
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC98322/
- Badges
- Science topic
- Similar topics
- Biological Science
- Microbiology
- Microorganisms
- Bacteria